Irritable Bowel Syndrome (IBS)

Latest News

Non-viable, Heat-inactivated Bifidobacterium bifidum MIMBb75 Improves IBS Symptoms

By

Dibash Kumar Das, PhD

Use of a heat-inactivated form of a probiotic was associated with significant reduction in abdominal pain as well as relief of symptoms in patients with irritable bowel syndrome.

Mindfulness-Based Stress Reduction May Cut IBS Symptoms

Mindfulness-based stress reduction training is associated with robust improvements in gastrointestinal symptoms for patients with irritable bowel syndrome.

Next-Gen Rechargeable Neurostimulator Implant Approved for Urinary, Bowel Dysfunction

By

Steve Duffy

The FDA has approved a new version of Axonics Modulation’s rechargeable implantable sacral neurostimulator (r-SNM) system that allows patients to decrease the frequency of charging to once a month.

Dead' Probiotic Treatment May Help Reduce Irritable Bowel Symptoms

Probiotic treatment with dead bacteria is better than placebo at alleviating symptoms of irritable bowel syndrome.

New Data on Peppermint Oil and Irritable Bowel Syndrome

By

Andy Kistler, MD, PharmD

A commonly used over-the-counter treatment for IBS is peppermint oil. The exact mechanism of action in IBS is not entirely known; however, it has been postulated that it may be mediated through smooth muscle relaxation, antimicrobial effects, modulation of pain receptors, and 5-hydroxytryptamine antagonism.

Tenapanor Demonstrates Efficacy, Tolerability, and Safety in Treating IBS-C

By

Gastroenterology Advisor Contributing Writer

Tenapanor 50 mg has demonstrated efficacy, tolerability, and safety in treating constipation-predominant irritable bowel syndrome.

Challenges, Controversies in Drug Safety Monitoring

By

Gastroenterology Advisor Contributing Writer

The FDA plays a critical role in the evaluation of drug safety prior to approval and following introduction into clinical practice.

No Distinct Microbiome Profile for IBS in Swedish Population

By

Lauren Dembeck, PhD

The researchers concluded that this is the first study to investigate the mucosa-associated gut microbiome in an adult population-based cohort and that no distinct microbial signature was observed in IBS.

Effects of Human Milk Oligosaccharides on Gastrointestinal Symptoms in IBS: Q&A With Dr Magnus Simrén

By

Dibash Kumar Das, PhD

Oral supplementation with 2 unique forms of human milk oligosaccharides can provide nutritional support that significantly reduces abnormal stool consistency, abdominal pain, and bloating and improves health-related quality of life in patients with IBS of all subtypes.

Zinc Deficiency May Perpetuate Irritable Bowel Syndrome Pathology/Symptoms

By

Gastroenterology Advisor Contributing Writer

Zinc deficiency may perpetuate the underlying pathophysiology of IBS as well as associated psychiatric conditions, via the role zinc plays in the “brain-gut” axis, the immune system, and gastrointestinal barrier integrity.

Rifaximin and Meaningful Pain Improvement in IBS With Diarrhea

By

Gastroenterology Advisor Contributing Writer

Rifaximin treatment resulted in meaningful pain improvements of abdominal pain in a high percentage of patients, irrespective of baseline severity category and treatment course.

Expert Q&A: Low-FODMAP Diet Risky in Patients With Eating Disorders

By

Tori Rodriguez, MA, LPC, AHC

In individuals with IBS, screening for an eating disorder or maladaptive eating is recommended prior to recommending the low-FODMAP diet.

Cognitive Therapy by Phone, Web May Ease Irritable Bowel Symptoms

Cognitive behavioral therapy (CBT) delivered via telephone and web is effective for relieving the symptoms of irritable bowel syndrome.

Risk for Developing Idiopathic Pulmonary Fibrosis Increased in IBD

Patients with inflammatory bowel disease (IBD), especially male patients, have an increased risk for development of idiopathic pulmonary fibrosis.

Eluxadoline Treatment Safe, Effective in IBS-D With Failed Loperamide Therapy

By

Gastroenterology Advisor Contributing Writer

This study prospective validates previous findings revealing eluxadoline to be a safe, effective IBS-D treatment in patients reporting inadequate symptom relief with prior loperamide use.

FDA Approves First-in-Class Treatment for IBS-C

By

Diana Ernst, RPh

The Food and Drug Administration (FDA) has approved Ibsrela (tenapanor; Ardelyx) for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults.

Eluxadoline: Efficacy and Safety for Irritable Bowel Syndrome With Diarrhea

By

Gastroenterology Advisor Contributing Writer

Eluxadoline appears to be a safe and effective treatment for the symptoms of irritable bowel syndrome with diarrhea (IBS-D) in patients with intact gallbladders who have previously reported inadequate relief with loperamide.

Low FODMAP Diet in Irritable Bowel Syndrome: Controversies and Practicality

By

C. Andrew Kistler, MD, PharmD

Further studies will need to look at different subtypes of IBS (IBS-diarrhea, IBS-constipation, IBS-mixed) and improved breath testing, as well as evaluating underlying gut microbiome profiles and how they may affect a response to a low FODMAP diet.

Irritable Bowel Syndrome and Vitamin D: Is There a Connection?

By

Mary E. Pollock, CRNP; Colleen Barrett, DNP, CRNP, FNP-BC

Low vitamin D levels have been linked to multiple diseases including some cancers, neurologic disorders, decrease in bone density, and cognitive decline in the elderly, and research suggests that a possible inflammatory response in the gut when vitamin D levels are low may cause irritable bowel syndrome.

Time-Saving Benefits of Point-of-Care Ultrasonography for Small Bowel Obstruction

By

Gastroenterology Advisor Contributing Writer

Compared with computed tomographic (CT) scan, point-of-care ultrasonography has demonstrated high accuracy in diagnosing small bowel obstruction in the emergency department, which may result in a significantly shorter time to diagnosis.